Nicolas Singewald

List of Publications by Year
in descending order

178 papers	10,238 citations	23500 58 h-index	43802 91 g-index

190 all docs	190 docs citations	190 times ranked	10151 citing authors

#	Article	IF	Citations
1	Neuronal circuits of fear extinction. European Journal of Neuroscience, 2010, 31, 599-612.	1.2	412
2	Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. , 2015, 149, 150-190.		340
3	Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs. Biological Psychiatry, 2003, 53, 275-283.	0.7	300
4	The role of substance P in stress and anxiety responses. Amino Acids, 2006, 31, 251-272.	1.2	256
5	Impaired Fear Extinction Learning and Cortico-Amygdala Circuit Abnormalities in a Common Genetic Mouse Strain. Journal of Neuroscience, 2008, 28, 8074-8085.	1.7	231
6	Substance P in the medial amygdala: Emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4280-4285.	3.3	201
7	Prefrontal inputs to the amygdala instruct fear extinction memory formation. Science Advances, 2015, 1, .	4.7	181
8	Release of neurotransmitters in the locus coeruleus. Progress in Neurobiology, 1998, 56, 237-267.	2.8	174
9	Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. European Journal of Neuroscience, 2003, 18, 143-148.	1.2	173
10	Release of Oxytocin in the Rat Central Amygdala Modulates Stress-Coping Behavior and the Release of Excitatory Amino Acids. Neuropsychopharmacology, 2005, 30, 223-230.	2.8	173
11	Single dose of <scp>l</scp> -dopa makes extinction memories context-independent and prevents the return of fear. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2428-36.	3.3	169
12	Isoform-specific regulation of mood behavior and pancreatic Î² cell and cardiovascular function by L-type Ca2+ channels. Journal of Clinical Investigation, 2004, 113, 1430-1439.	3.9	168
13	Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: Focus on vasopressin and glyoxalase-I. Neuroscience and Biobehavioral Reviews, 2007, 31, 89-102.	2.9	167
14	Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochemical Society Transactions, 2006, 34, 903-909.	1.6	161
15	Acute transcranial magnetic stimulation of frontal brain regions selectively modulates the release of vasopressin, biogenic amines and amino acids in the rat brain. European Journal of Neuroscience, 2000, 12, 3713-3720.	1.2	146
16	Prodynorphin-Derived Peptides Are Critical Modulators of Anxiety and Regulate Neurochemistry and Corticosterone. Neuropsychopharmacology, 2009, 34, 775-785.	2.8	143
17	Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience, 2000, 98, 759-770.	1.1	141
18	Magnesium-deficient diet alters depression- and anxiety-related behavior in miceâ€"influence of desipramine and Hypericum perforatum extract. Neuropharmacology, 2004, 47, 1189-1197.	2.0	139

#	Article	IF	Citations
19	Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug. Nature Communications, 2015, 6, 8466.	5.8	139
20	Impaired Repression at a Vasopressin Promoter Polymorphism Underlies Overexpression of Vasopressin in a Rat Model of Trait Anxiety. Journal of Neuroscience, 2004, 24, 7762-7770.	1.7	137
21	The Central and Basolateral Amygdala Are Critical Sites of Neuropeptide Y/Y2 Receptor-Mediated Regulation of Anxiety and Depression. Journal of Neuroscience, 2010, 30, 6282-6290.	1.7	132
22	Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. , 2019, 204, 107402.		132
23	The Modulatory Role of the Lateral Septum on Neuroendocrine and Behavioral Stress Responses. Neuropsychopharmacology, 2011, 36, 793-804.	2.8	131
24	Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Molecular Psychiatry, 2008, 13, 1028-1042.	4.1	129
25	Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice. Amino Acids, 2009, 36, 147-158.	1.2	129
26	Neurobiological correlates of high (HAB) versus low anxiety-related behavior (LAB): differential Fos expression in HAB and LAB rats. Biological Psychiatry, 2004, 55, 715-723.	0.7	121
27	Individual differences in recovery from traumatic fear. Trends in Neurosciences, 2013, 36, 23-31.	4.2	120
28	Different Fear States Engage Distinct Networks within the Intercalated Cell Clusters of the Amygdala. Journal of Neuroscience, 2011, 31, 5131-5144.	1.7	118
29	Magnesium deficiency induces anxiety and HPA axis dysregulation: Modulation by therapeutic drug treatment. Neuropharmacology, 2012, 62, 304-312.	2.0	117
30	Induction of Î”FosB in the Periaqueductal Gray by Stress Promotes Active Coping Responses. Neuron, 2007, 55, 289-300.	3.8	114
31	Tachykinin Receptors as Therapeutic Targets in Stress-Related Disorders. Current Pharmaceutical Design, 2009, 15, 1647-1674.	0.9	109
32	Impaired extinction of learned fear in rats selectively bred for high anxiety â€“ evidence of altered neuronal processing in prefrontalâ€amygdala pathways. European Journal of Neuroscience, 2008, 28, 2299-2309.	1.2	108
33	Genetic predisposition to anxiety-related behavior determines coping style, neuroendocrine responses, and neuronal activation during social defeat.. Behavioral Neuroscience, 2006, 120, 60-71.	0.6	104
34	Fetal Down Syndrome Brains Exhibit Aberrant Levels of Neurotransmitters Critical for Normal Brain Development. Pediatrics, 2007, 120, e1465-e1471.	1.0	101
35	HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?. Biochemical Society Transactions, 2014, 42, 569-581.	1.6	99
36	Differences between GABA levels in Alzheimer's disease and Down syndrome with Alzheimer-like neuropathology. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 363, 139-145.	1.4	95

#	Article	IF	Citations
37	Genetic Strain Differences in Learned Fear Inhibition Associated with Variation in Neuroendocrine, Autonomic, and Amygdala Dendritic Phenotypes. Neuropsychopharmacology, 2012, 37, 1534-1547.	2.8	93
38	Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neuroscience and Biobehavioral Reviews, 2007, 31, 18-40.	2.9	91
39	CaV1.3 L-type Ca2+ channels modulate depression-like behaviour in mice independent of deaf phenotype. International Journal of Neuropsychopharmacology, 2010, 13, 499.	1.0	90
40	Individual differences in stress susceptibility and stress inhibitory mechanisms. Current Opinion in Behavioral Sciences, 2017, 14, 54-64.	2.0	90
41	Substance P in Stress and Anxiety. Annals of the New York Academy of Sciences, 2008, 1144, 61-73.	1.8	81
42	Rodent models of impaired fear extinction. Psychopharmacology, 2019, 236, 21-32.	1.5	80
43	Reduced anxietyâ€like and depressionâ€related behavior in neuropeptide Y Y4 receptor knockout mice. Genes, Brain and Behavior, 2008, 7, 532-542.	1.1	77
44	Rescue of Impaired Fear Extinction and Normalization of Cortico-Amygdala Circuit Dysfunction in a Genetic Mouse Model by Dietary Zinc Restriction. Journal of Neuroscience, 2010, 30, 13586-13596.	1.7	77
45	Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis. Trends in Pharmacological Sciences, 1996, 17, 356-363.	4.0	76
46	Effect of chronic psychosocial stress-induced by subordinate colony (CSC) housing on brain neuronal activity patterns in mice. Stress, 2009, 12, 58-69.	0.8	75
47	Decreased social interaction in aged rats may not reflect changes in anxiety-related behaviour. Behavioural Brain Research, 2004, 151, 1-8.	1.2	74
48	Differences in serotonergic neurotransmission between rats displaying high or low anxiety/depression-like behaviour: effects of chronic paroxetine treatment. Journal of Neurochemistry, 2005, 92, 1170-1179.	2.1	74
49	Altered Brain Activation Pattern Associated With Drug-Induced Attenuation of Enhanced Depression-Like Behavior in Rats Bred for High Anxiety. Biological Psychiatry, 2007, 61, 782-796.	0.7	73
50	Increased novelty-induced motor activity and reduced depression-like behavior in neuropeptide Y (NPY)â€“Y4 receptor knockout mice. Neuroscience, 2009, 158, 1717-1730.	1.1	72
51	Altered GABA transmission in a mouse model of increased trait anxiety. Neuroscience, 2011, 183, 71-80.	1.1	71
52	Behavioral and Neurobiological Effects of Deep Brain Stimulation in a Mouse Model of High Anxiety- and Depression-Like Behavior. Neuropsychopharmacology, 2013, 38, 1234-1244.	2.8	70
53	The clinical implications of mouse models of enhanced anxiety. Future Neurology, 2011, 6, 531-571.	0.9	68
54	Satb2 determines miRNA expression and long-term memory in the adult central nervous system. ELife, 2016, 5, .	2.8	68

#	Article	IF	Citations
55	High trait anxiety and hyporeactivity to stress of the dorsomedial prefrontal cortex: a combined phMRI and Fos study in rats. NeuroImage, 2004, 23, 382-391.	2.1	67
56	Deep brain stimulation, histone deacetylase inhibitors and glutamatergic drugs rescue resistance to fear extinction in a genetic mouse model. Neuropharmacology, 2013, 64, 414-423.	2.0	67
57	Impaired Pavlovian fear extinction is a common phenotype across genetic lineages of the 129 inbred mouse strain. Genes, Brain and Behavior, 2009, 8, 744-752.	1.1	65
58	Prefrontal single-unit firing associated with deficient extinction in mice. Neurobiology of Learning and Memory, 2014, 113, 69-81.	1.0	65
59	Differential Stress-Induced Neuronal Activation Patterns in Mouse Lines Selectively Bred for High, Normal or Low Anxiety. PLoS ONE, 2009, 4, e5346.	1.1	65
60	Release of excitatory and inhibitory amino acids from the locus coeruleus of conscious rats by cardiovascular stimuli and various forms of acute stress. Brain Research, 1995, 704, 42-50.	1.1	64
61	Durable fear memories require PSD-95. Molecular Psychiatry, 2015, 20, 901-912.	4.1	64
62	MicroRNA-Mediated Rescue of Fear Extinction Memory by miR-144-3p in Extinction-Impaired Mice. Biological Psychiatry, 2017, 81, 979-989.	0.7	59
63	Neuroanatomical substrates involved in the anxiogenic-like effect of acute fluoxetine treatment. Neuropharmacology, 2002, 43, 1238-1248.	2.0	58
64	Anxiety- rather than depression-like behavior is associated with adult neurogenesis in a female mouse model of higher trait anxiety- and comorbid depression-like behavior. Translational Psychiatry, 2012, 2, e171-e171.	2.4	57
65	A Hypomorphic Vasopressin Allele Prevents Anxiety-Related Behavior. PLoS ONE, 2009, 4, e5129.	1.1	56
66	The L-type calcium channel Cav1.3 is required for proper hippocampal neurogenesis and cognitive functions. Cell Calcium, 2015, 58, 606-616.	1.1	55
67	Reliability of high and low anxiety-related behaviour:. Behavioural Brain Research, 2002, 136, 227-237.	1.2	54
68	Brain activation pattern induced by stimulation of L-type Ca2+-channels: Contribution of CaV1.3 and CaV1.2 isoforms. Neuroscience, 2006, 139, 1005-1015.	1.1	54
69	Enhanced Fear Expression in a Psychopathological Mouse Model of Trait Anxiety: Pharmacological Interventions. PLoS ONE, 2011, 6, e16849.	1.1	53
70	Neuropeptide S alters anxiety, but not depression-like behaviour in Flinders Sensitive Line rats: a genetic animal model of depression. International Journal of Neuropsychopharmacology, 2012, 15, 375-387.	1.0	53
71	Enhancing dopaminergic signaling and histone acetylation promotes long-term rescue of deficient fear extinction. Translational Psychiatry, 2016, 6, e974-e974.	2.4	53
72	Release of Serotonin in the Rat Locus Coeruleus: Effects of Cardiovascular, Stressful and Noxious Stimuli. European Journal of Neuroscience, 1997, 9, 556-562.	1.2	50

#	Article	IF	Citations
73	Selective Breeding for High Anxiety Introduces a Synonymous SNP That Increases Neuropeptide S Receptor Activity. Journal of Neuroscience, 2015, 35, 4599-4613.	1.7	50
74	Modulation of basal and stressâ€induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist Lâ€822429. Journal of Neurochemistry, 2008, 106, 2476-2488.	2.1	49
75	Increased in vivo release of neuropeptide S in the amygdala of freely moving rats after local depolarisation and emotional stress. Amino Acids, 2011, 41, 991-996.	1.2	46
76	Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: Experimental evidence. Experimental Neurology, 2013, 247, 531-536.	2.0	46
77	Neurokinin 1 Receptor Antagonism Promotes Active Stress Coping Via Enhanced Septal 5-HT Transmission. Neuropsychopharmacology, 2008, 33, 1929-1941.	2.8	45
78	Bidirectional rescue of extreme genetic predispositions to anxiety: impact of CRH receptor 1 as epigenetic plasticity gene in the amygdala. Translational Psychiatry, 2014, 4, e359-e359.	2.4	45
79	Changes in brain protein expression are linked to magnesium restriction-induced depression-like behavior. Amino Acids, 2011, 40, 1231-1248.	1.2	44
80	Cell-type-specific tuning of Cav1.3 Ca2+-channels by a C-terminal automodulatory domain. Frontiers in Cellular Neuroscience, 2015, 9, 309.	1.8	41
81	Neuroinflammatory alterations in trait anxiety: modulatory effects of minocycline. Translational Psychiatry, 2020, 10, 256.	2.4	39
82	Airjet and FG-7142-induced Fos expression differs in rats selectively bred for high and low anxiety-related behavior. Neuropharmacology, 2006, 50, 1048-1058.	2.0	38
83	GPR39 Zn2+-sensing receptor: A new target in antidepressant development?. Journal of Affective Disorders, 2015, 174, 89-100.	2.0	38
84	Central amygdala micro-circuits mediate fear extinction. Nature Communications, 2021, 12, 4156.	5.8	38
85	Release of glutamate and GABA in the amygdala of conscious rats by acute stress and baroreceptor activation: differences between SHR and WKY rats. Brain Research, 2000, 864, 138-141.	1.1	36
86	Neural substrates for the distinct effects of presynaptic group III metabotropic glutamate receptors on extinction of contextual fear conditioning in mice. Neuropharmacology, 2013, 66, 274-289.	2.0	35
87	Noradrenaline release in the locus coeruleus of conscious rats is triggered by drugs, stress and blood pressure changes. NeuroReport, 1999, 10, 1583-1587.	0.6	34
88	Diabetes insipidus and, partially, low anxietyâ€related behaviour are linked to a SNPâ€associated vasopressin deficit in LAB mice. European Journal of Neuroscience, 2007, 26, 2857-2864.	1.2	34
89	Catecholamine release in the locus coeruleus is modified by experimentally induced changes in haemodynamics. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 21-7.	1.4	33
90	Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn-Schmiedeberg's Archives of Pharmacology, 2007, 376, 73-82.	1.4	33

#	Article	IF	Citations
91	A mouse model of high trait anxiety shows reduced heart rate variability that can be reversed by anxiolytic drug treatment. International Journal of Neuropsychopharmacology, 2011, 14, 1341-1355.	1.0	33
92	Depletion of nucleus accumbens dopamine leads to impaired reward and aversion processing in mice: Relevance to motivation pathologies. Neuropharmacology, 2016, 109, 306-319.	2.0	33
93	Role of L-type Ca²⁺channel isoforms in the extinction of conditioned fear. Learning and Memory, 2008, 15, 378-386.	0.5	32
94	Circadian abnormalities in a mouse model of high trait anxiety and depression. Annals of Medicine, 2014, 46, 148-154.	1.5	32
95	Influence of excitatory amino acids on basal and sensory stimuli-induced release of 5-HT in the locus coeruleus. British Journal of Pharmacology, 1998, 123, 746-752.	2.7	31
96	Conditional CRF receptor 1 knockout mice show altered neuronal activation pattern to mild anxiogenic challenge. Psychopharmacology, 2006, 188, 374-385.	1.5	30
97	Sub-chronic dietary tryptophan depletion â€“ An animal model of depression with improved face and good construct validity. Journal of Psychiatric Research, 2012, 46, 239-247.	1.5	30
98	Increased cocaine-induced conditioned place preference during periadolescence in maternally separated male BALB/c mice: the role of cortical BDNF, microRNA-212, and MeCP2. Psychopharmacology, 2016, 233, 3279-3288.	1.5	30
99	Microglial ablation in rats disrupts the circadian system. FASEB Journal, 2021, 35, e21195.	0.2	30
100	Extracellular amino acid levels in the paraventricular nucleus and the central amygdala in high- and low-anxiety dams rats during maternal aggression: Regulation by oxytocin. Stress, 2007, 10, 261-270.	0.8	29
101	Serotonin (5-HT) in brains of adult patients with Down Syndrome. , 1999, 57, 221-232.		29
102	Corticotropin-releasing factor modulates basal and stress-induced excitatory amino acid release in the locus coeruleus of conscious rats. Neuroscience Letters, 1996, 204, 45-48.	1.0	28
103	5-HT receptor subtypes involved in the anxiogenic-like action and associated Fos response of acute fluoxetine treatment in rats. Psychopharmacology, 2006, 185, 282-288.	1.5	28
104	Increased levels of conditioned fear and avoidance behavior coincide with changes in phosphorylation of the protein kinase B (AKT) within the amygdala in a mouse model of extremes in trait anxiety. Neurobiology of Learning and Memory, 2012, 98, 56-65.	1.0	27
105	Combined Neuropeptide S and D-Cycloserine Augmentation Prevents the Return of Fear in Extinction-Impaired Rodents: Advantage of Dual versus Single Drug Approaches. International Journal of Neuropsychopharmacology, 2016, 19, pyv128.	1.0	27
106	The Good, the Bad and the Unknown Aspects of Ghrelin in Stress Coping and Stress-Related Psychiatric Disorders. Frontiers in Synaptic Neuroscience, 2020, 12, 594484.	1.3	26
107	Release of endogenous GABA in the posterior hypothalamus of the conscious rat; effects of drugs and experimentally induced blood pressure changes. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 402-406.	1.4	25
108	Structural and Functional Remodeling of Amygdala GABAergic Synapses in Associative Fear Learning. Neuron, 2019, 104, 781-794.e4.	3.8	24

#	Article	IF	Citations
109	On the objectivity, reliability, and validity of deep learning enabled bioimage analyses. ELife, 2020, 9, .	2.8	24
110	Effects of blood pressure changes on the catecholamine release in the locus coeruleus of cats anaesthetized with pentobarbital or chloralose. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 348, 242-8.	1.4	23
111	Aldosterone increases earlier than corticosterone in new animal models of depression: Is this an early marker?. Journal of Psychiatric Research, 2012, 46, 1394-1397.	1.5	23
112	Temporal factors in the extinction of fear in inbred mouse strains differing in extinction efficacy. Biology of Mood & Anxiety Disorders, 2013, 3, 13.	4.7	23
113	Structureâ€“Activity Relationships of Novel Thiazole-Based Modafinil Analogues Acting at Monoamine Transporters. Journal of Medicinal Chemistry, 2020, 63, 391-417.	2.9	23
114	Genetic functional inactivation of neuronal nitric oxide synthase affects stress-related Fos expression in specific brain regions. Cellular and Molecular Life Sciences, 2004, 61, 1498-1506.	2.4	22
115	Fluoxetine normalizes disrupted light-induced entrainment, fragmented ultradian rhythms and altered hippocampal clock gene expression in an animal model of high trait anxiety- and depression-related behavior. Annals of Medicine, 2016, 48, 17-27.	1.5	22
116	Role of MicroRNAs in Anxiety and Anxiety-Related Disorders. Current Topics in Behavioral Neurosciences, 2019, 42, 185-219.	0.8	22
117	Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis. , 1996, 17, 356-356.		22
118	Social interaction reward in rats has antiâ€stress effects. Addiction Biology, 2021, 26, e12878.	1.4	21
119	Effects of neuroactive compounds, noxious and cardiovascular stimuli on the release of amino acids in the rat locus coeruleus. Neuroscience Letters, 1994, 180, 55-58.	1.0	19
120	Reinstatement of synaptic plasticity in the aging brain through specific dopamine transporter inhibition. Molecular Psychiatry, 2021, 26, 7076-7090.	4.1	19
121	The release of inhibitory amino acids in the hypothalamus is tonically modified by impulses from aortic baroreceptors as a consequence of blood pressure fluctuations. Naunyn-Schmiedeberg's Archives of Pharmacology, 1997, 356, 348-355.	1.4	18
122	Role of nitric oxide in the stress-induced release of serotonin in the locus coeruleus. Naunyn-Schmiedeberg's Archives of Pharmacology, 2001, 364, 105-109.	1.4	18
123	Individual contribution of metabotropic glutamate receptor (mGlu) 2 and 3 to c-Fos expression pattern evoked by mGlu2/3 antagonism. Psychopharmacology, 2008, 201, 1-13.	1.5	18
124	Epigenetic Mechanisms Within the Cingulate Cortex Regulate Innate Anxiety-Like Behavior. International Journal of Neuropsychopharmacology, 2019, 22, 317-328.	1.0	18
125	Exploring the role of neuropeptide S in the regulation of arousal: a functional anatomical study. Brain Structure and Function, 2016, 221, 3521-3546.	1.2	17
126	Inhibition of catecholamine (noradrenaline, dopamine) release in the locus coeruleus and the hypothalamus by baroreceptor activation: identification of the involved baroreceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1995, 352, 291-6.	1.4	16

#	Article	IF	Citations
127	The release of catecholamines in hypothalamus and locus coeruleus is modulated by peripheral chemoreceptors. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 360, 428-434.	1.4	16
128	Dietary magnesium restriction reduces amygdalaâ€“hypothalamic GluN1 receptor complex levels in mice. Brain Structure and Function, 2015, 220, 2209-2221.	1.2	16
129	Differential Effects of Novel Dopamine Reuptake Inhibitors on Interference With Long-Term Social Memory in Mice. Frontiers in Behavioral Neuroscience, 2019, 13, 63.	1.0	16
130	Involvement of biogenic amines and amino acids in the central regulation of cardiovascular homeostasis. Trends in Pharmacological Sciences, 1996, 17, 356-63.	4.0	16
131	Disturbances in blood pressure homeostasis modify GABA release in the locus coeruleus. NeuroReport, 1994, 5, 1709-1712.	0.6	15
132	Potential of microRNAs as novel targets in the alleviation of pathological fear. Genes, Brain and Behavior, 2018, 17, e12427.	1.1	15
133	Increased conditioned place preference for cocaine in high anxiety related behavior (HAB) mice is associated with an increased activation in the accumbens corridor. Frontiers in Behavioral Neuroscience, 2014, 8, 441.	1.0	14
134	Reduced Anxiety-Like Behavior and Altered Hippocampal Morphology in Female p75NTRexon IVâ^'/â^' Mice. Frontiers in Behavioral Neuroscience, 2016, 10, 103.	1.0	14
135	Dysregulation of select ATP-dependent chromatin remodeling factors in high trait anxiety. Behavioural Brain Research, 2016, 311, 141-146.	1.2	14
136	Pharmacophore Modeling, Virtual Screening, and in Vitro Testing Reveal Haloperidol, Eprazinone, and Fenbutrazate as Neurokinin Receptors Ligands. Journal of Chemical Information and Modeling, 2014, 54, 1747-1757.	2.5	13
137	Substance P excites GABAergic neurons in the mouse central amygdala through neurokinin 1 receptor activation. Journal of Neurophysiology, 2015, 114, 2500-2508.	0.9	13
138	Effects of disrupted ghrelin receptor function on fear processing, anxiety and saccharin preference in mice. Psychoneuroendocrinology, 2019, 110, 104430.	1.3	13
139	Role for Chromatin Remodeling Factor Chd1 in Learning and Memory. Frontiers in Molecular Neuroscience, 2019, 12, 3.	1.4	13
140	Differential amino acid transmission in the locus coeruleus of Wistar Kyoto and spontaneously hypertensive rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 370, 381-387.	1.4	12
141	Inhibitory Function of the Dorsomedial Hypothalamic Nucleus on the Hypothalamicâ€“Pituitaryâ€“Adrenal Axis Response to an Emotional Stressor but not Immune Challenge. Journal of Neuroendocrinology, 2013, 25, 48-55.	1.2	12
142	Cortical reorganization processes in meditation naÃ¯ve participants induced by 7 weeks focused attention meditation training. Behavioural Brain Research, 2020, 395, 112828.	1.2	12
143	Sinoaortic denervation abolishes blood pressure-induced GABA release in the locus coeruleus of conscious rats. Neuroscience Letters, 2006, 393, 194-199.	1.0	11
144	Effect of neuropeptide Y Y2 receptor deletion on emotional stressâ€induced neuronal activation in mice. Synapse, 2009, 63, 236-246.	0.6	11

#	Article	IF	Citations
145	Evaluation of the effect of chronic antidepressant treatment on neurokinin-1 receptor expression in the rat brain. Neuropharmacology, 2004, 46, 1177-1183.	2.0	10
146	Loss of Nogo receptor homolog NgR2 alters spine morphology of CA1 neurons and emotionality in adult mice. Frontiers in Behavioral Neuroscience, 2014, 8, 175.	1.0	10
147	Altered sleep behavior in a genetic mouse model of impaired fear extinction. Scientific Reports, 2021, 11, 8978.	1.6	10
148	Impaired Contextual Fear Extinction Learning is Associated with Aberrant Regulation of CHD-Type Chromatin Remodeling Factors. Frontiers in Behavioral Neuroscience, 2015, 9, 313.	1.0	9
149	Effects of local MAO inhibition in the locus coeruleus on extracellular serotonin and 5-HIAA during exposure to sensory and cardiovascular stimuli. Naunyn-Schmiedeberg's Archives of Pharmacology, 1999, 359, 187-193.	1.4	8
150	Effects of ghrelin receptor activation on forebrain dopamine release, conditioned fear and fear extinction in C57BL/6J mice. Journal of Neurochemistry, 2020, 154, 389-403.	2.1	8
151	Peripheral chemoreceptor activation enhances 5-hydroxytryptamine release in the locus coeruleus of conscious rats. Neuroscience Letters, 2000, 289, 17-20.	1.0	6
152	Serotonin1A-receptor-dependent signaling proteins in mouse hippocampus. Neuropharmacology, 2009, 57, 556-566.	2.0	4
153	Increased amygdalar metabotropic glutamate receptor 7 mRNA in a genetic mouse model of impaired fear extinction. Psychopharmacology, 2019, 236, 265-272.	1.5	4
154	Shortâ€term meditation training influences brain energy metabolism: A pilot study on ³¹P MR spectroscopy. Brain and Behavior, 2021, 11, e01914.	1.0	4
155	The Novel Analogue of Modafinil CE-158 Protects Social Memory against Interference and Triggers the Release of Dopamine in the Nucleus Accumbens of Mice. Biomolecules, 2022, 12, 506.	1.8	4
156	New pharmacological strategies for augmenting extinction learning in anxiety disorders. E-Neuroforum, 2017, 23, A145-A156.	0.2	3
157	Brain Energy Metabolism in Two States of Mind Measured by Phosphorous Magnetic Resonance Spectroscopy. Frontiers in Human Neuroscience, 2021, 15, 686433.	1.0	3
158	Stereoselective and region-specific induction of immediate early gene expression in rat parietal cortex by blockade of neurokinin 1 receptors. Journal of Psychopharmacology, 2006, 20, 570-576.	2.0	2
159	Enhanced fear expression in a psychphathological mouse model of trait anxiety: pharmacological interventions. BMC Pharmacology, 2010, 10, .	0.4	2
160	Chronic treatment with a selective neurokinin-1 receptor antagonist in a mouse model of trait anxiety and depression: focus on behaviour and neuropeptidergic mechanisms. BMC Pharmacology, 2008, 8, .	0.4	1
161	Fear learning triggers structural changes at GABAergic synapses in the basal amygdala. BMC Pharmacology, 2010, 10, .	0.4	1
162	S.24.03 Rodent models of impaired fear extinction: therapeutic approaches. European Neuropsychopharmacology, 2011, 21, S224.	0.3	1

#	Article	IF	Citations
163	129S1/SvImJ mice display impaired contextual fear extinction, enhanced fear incubation and deficit extinction consolidation phenotypes: rescue via pharmacological and non-pharmacological treatments. BMC Pharmacology, 2011, 11, .	0.4	1
164	Adult neurogenesis in a psychopathological mouse model of trait anxiety and comorbid depression-like behavior: effect of antidepressants. BMC Pharmacology, 2009, 9, .	0.4	0
165	CaV1.3 L-type calcium channels modulate depression-like behavior in mice independent of deaf phenotype. BMC Pharmacology, 2009, 9, .	0.4	0
166	Endogenous dynorphin in emotional control and stress response. BMC Pharmacology, 2009, 9, .	0.4	0
167	S.24.02 Genetic variation driving fear and anxiety. European Neuropsychopharmacology, 2011, 21, S224.	0.3	0
168	Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment. BMC Pharmacology, 2011, 11, .	0.4	0
169	Fear learning induces structural and functional plasticity at GABAergic synapses in the basolateral amygdala. BMC Pharmacology, 2011, 11, A42.	0.4	0
170	Septal urocortin 3 modulates stress-coping behaviour but not hypothalamic-pituitary-adrenal axis activity during forced swimming. BMC Pharmacology, 2011, 11, .	0.4	0
171	The galanin system in depression and antidepressant treatment: focus on the locus coeruleus. BMC Pharmacology & Toxicology, 2012, 13, .	1.0	0
172	Histone deacetylase inhibitors, glutamatergic drugs and deep brain stimulation rescue resistance to fear extinction in a genetic mouse model. BMC Pharmacology & Toxicology, 2012, 13, .	1.0	0
173	Neurobiological correlates of successful deep brain stimulation in a mouse model of high trait affect. BMC Pharmacology & Toxicology, 2012, 13, .	1.0	0
174	A mouse model to study the C-terminal regulation of CaV1.3 L-type calcium channels. BMC Pharmacology & Toxicology, 2012, 13, .	1.0	0
175	A Novel Animal Model to Study the InÂVivo Role of a C-Terminal Regulatory Domain in Cav1.3 L-Type Calcium Channels. Biophysical Journal, 2013, 104, 459a.	0.2	0
176	S.20.02 Anxiety, depression and adult neurogenesis. European Neuropsychopharmacology, 2014, 24, S136-S137.	0.3	0
177	Neue pharmakologische Strategien zur Augmentation von Extinktionslernen in der Angsttherapie. E-Neuroforum, 2017, 23, 197-211.	0.2	0
178	Potential anxiolytics acting via the neuropeptide S-receptor. Planta Medica, 2012, 78, .	0.7	0